Physician profile
Eric T Baumann
NPI 1871559708
$4,707.46
in general payments reported to CMS, 2019-2025
28 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $885 · 2021: $1,074 · 2022: $241 · 2023: $861 · 2024: $282 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,011.59 | 2021-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $744.28 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Johnson & Johnson Health Care Systems INC. | $459.00 | 2021 | |
| Medtronic USA, INC. | $371.86 | 2019-2020 | |
| Allergan, INC. | $308.23 | 2019-2021 | |
| Nevro Corp. | $299.20 | 2019-2021 | |
| Amgen INC. | $248.86 | 2020-2025 | Evenity, Prolia |
| Biodelivery Sciences International, INC. | $205.51 | 2019-2021 | |
| Pfizer INC. | $189.80 | 2019-2021 | |
| Boston Scientific Corporation | $137.94 | 2025 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $115.13 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $99.29 | 2021 | |
| Bioventus LLC | $73.98 | 2021-2024 | Durolane, Durolane |
| Teva Pharmaceuticals USA, INC. | $70.58 | 2020-2021 | |
| Abbvie INC. | $58.04 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $57.57 | 2020-2023 | Belbuca |
| Novartis Pharmaceuticals Corporation | $37.16 | 2019-2020 | |
| Ibsa Pharma INC. | $37.02 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $25.33 | 2025 | |
| Fidia Pharma USA INC. | $24.96 | 2024 | Hymovis |
| Daiichi Sankyo INC. | $24.49 | 2019 | |
| Globus Medical, INC. | $20.56 | 2025 | Senza |
| Lilly USA, LLC | $17.90 | 2023 | Mounjaro |
| International Rehabilitative Sciences, INC | $14.93 | 2024 | Rs 4i Plus Sequential Stimulator |
| Electronic Waveform Lab, INC. | $14.82 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.61 | 2021 | |
| Merz North America, INC. | $13.49 | 2020 | |
| Redhill Biopharma INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Baumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.